Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

2013514 citationsJournal Articlehybrid Open Access

Authors

Denise A. Yardley · Sarah Cannon Research Institute

Shinzaburo Noguchi · Osaka University

Kathleen I. Pritchard · Sunnybrook Health Science Centre

Howard A. Burris · Tennessee Oncology

José Baselga · Memorial Sloan Kettering Cancer Center

Michael Gnant · Medical University of Vienna

Gabriel N. Hortobágyi

Abstract

The addition of everolimus to exemestane markedly prolonged PFS in patients with HR(+) advanced BC with disease recurrence/progression following prior NSAIs. These results further support the use of everolimus plus exemestane in this patient population. ClinicalTrials.gov #NCT00863655.

Topics & Keywords

Advanced Breast Cancer Therapies PI3K/AKT/mTOR signaling in cancer Estrogen and related hormone effects

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Advances in Therapy

Volume 30, Issue 10, pp. 870-884

DOI: 10.1007/s12325-013-0060-1

Field-Weighted Citation Impact: 31.04